Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights

Chen, Wenshuo; Chen, Haijin; Fu, Shudan; Lin, Xiaohua; Zhang, Zheng; Zhang, Jinlong

doi:10.1007/s00449-020-02380-y

Cited by 4 publications

(3 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these data may provide insight into whether local TNF-α inhibition in IBD is feasible, induces a clinically relevant response, and to some extent the mechanism of action of anti-TNF-α therapy in IBD. Of note, research shows an interplay between systemic anti-TNF-α therapy and a favorable response related to the effects on the microbiome [ 66 , 67 , 68 , 69 , 168 ]. Currently it is unclear whether local TNF-α inhibition at the site of inflammation induces these same effects to the same extent.…”

Section: Clinical Studies On Local Tnf-α Inhibitionmentioning

confidence: 99%

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory cytokine tumor necrosis factor-α (TNF-α) are associated with disease activity and severity. Anti-TNF-α therapy is administered systemically and efficacious in the treatment of IBD. However, systemic exposure is associated with adverse events that may impede therapeutic treatment. Clinical studies show that the efficacy correlates with immunological effects localized in the gastrointestinal tract (GIT) as opposed to systemic effects. These data suggest that site-specific TNF-α inhibition in IBD may be efficacious with fewer expected side effects related to systemic exposure. We therefore reviewed the available literature that investigated the efficacy or feasibility of local TNF-α inhibition in IBD. A literature search was performed on PubMed with given search terms and strategy. Of 8739 hits, 48 citations were included in this review. These studies ranged from animal studies to randomized placebo-controlled clinical trials. In these studies, local anti-TNF-α therapy was achieved with antibodies, antisense oligonucleotides (ASO), small interfering RNA (siRNA), microRNA (miRNA) and genetically modified organisms. This narrative review summarizes and discusses these approaches in view of the clinical relevance of local TNF-α inhibition in IBD.

show abstract

Section: Clinical Studies On Local Tnf-α Inhibitionmentioning

confidence: 99%

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Biologic agents, primarily those targeting TNFα, have exhibited transformative efficacy and a reassuring safety profile during pregnancy [26,28]. Emerging therapies such as other biologics and JAK inhibitors offer alternative avenues, particularly in refractory cases, although their safety profiles during gestation require further elucidation [33][34][35][36]. The therapeutic strategy mandates individualized treatment plans, meticulous disease monitoring, and prompt interventions, integrated through a patient-centric model that considers the complexities of the disease states and the safety profiles of available medications [6,25,37,38].…”

Section: Pharmacological Considerations In Managing Ibd During Pregnancymentioning

confidence: 99%

From Tummy to Mommy: The Impact of Inflammatory Bowel Disease on Pregnancy

2024

Japan J Med Sci

View full text Add to dashboard Cite

This review examines the relationship between Inflammatory Bowel Disease (IBD) and pregnancy. Focusing on women of reproductive age, it explores the epidemiological impact, management challenges, and pharmacological considerations of IBD in pregnancy. The review highlights the importance of maintaining disease remission, the role of hormonal and immunological changes, and the necessity of a multidisciplinary approach for optimal maternal and fetal outcomes. Additionally, it discusses the significance of diet and the microbiome in managing pregnant IBD patients and outlines current medical guidelines and recommendations. The review concludes by suggesting areas for future research, emphasizing the need for comprehensive, individualized, and evidence-based care for pregnant women with IBD

show abstract

“…ICAM-1 is a glycoprotein expressed on the surface of intestinal epithelial cells and vascular endothelial cells, with promising results in terms of UC management, including safety and potentially long-lasting effects. Cobitolimod, an AGO-simulating bacterial DNA used to activate Toll-like receptors 9, is another relevant example [ 96 ]. To date, the clinically approved targeted therapies (i.e., monoclonal antibodies and small molecules) constitute the standard of care for moderate-to-severe IBD; however, they are only effective in a portion of the patients [ 81 ].…”

Section: Ibd Symptoms and Treatment Optionsmentioning

confidence: 99%

Drug Targeting of Inflammatory Bowel Diseases by Biomolecules

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a group of disabling, destructive and incurable immune-mediated inflammatory diseases comprising Crohn’s disease (CD) and ulcerative colitis (UC), disorders that are highly prevalent worldwide and demand a large investment in healthcare. A persistent inflammatory state enables the dysfunction and destruction of healthy tissue, hindering the initiation and endurance of wound healing. Current treatments are ineffective at counteracting disease progression. Further, increased risk of serious side effects, other comorbidities and/or opportunistic infections highlight the need for effective treatment options. Gut microbiota, the key to preserving a healthy state, may, alternatively, increase a patient’s susceptibility to IBD onset and development given a relevant bacterial dysbiosis. Hence, the main goal of this review is to showcase the main conventional and emerging therapies for IBD, including microbiota-inspired untargeted and targeted approaches (such as phage therapy) to infection control. Special recognition is given to existing targeted strategies with biologics (via monoclonal antibodies, small molecules and nucleic acids) and stimuli-responsive (pH-, enzyme- and reactive oxygen species-triggered release), polymer-based nanomedicine that is specifically directed towards the regulation of inflammation overload (with some nanosystems additionally functionalized with carbohydrates or peptides directed towards M1-macrophages). The overall goal is to restore gut balance and decrease IBD’s societal impact.

show abstract

Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights

Cited by 4 publications

References 95 publications

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease

From Tummy to Mommy: The Impact of Inflammatory Bowel Disease on Pregnancy

Drug Targeting of Inflammatory Bowel Diseases by Biomolecules

Contact Info

Product

Resources

About